rigel pharmaceuticals new phase  study aiha research study now recruiting in the us learn more rigel submits nda for fostamatinib in chronic immune thrombocytopenia itp view press release pipeline news  events clinical trials investors rigel pipeline pipeline pipeline product  indication pre clinical phase  phase  phase  nda review fostamatinib  itpindication immune thrombocytopeniatarget syk fostamatinib itp  phase  fostamatinib  iganindication iga nephropathy target syk fostamatinib igan  phase  fostamatinib  aihaindication autoimmune hemolytic anemiatarget syk fostamatinib aiha  phase  r bgbindication cancer partner bergenbio r bgb  phase b mdm inhibitor dsindication cancer partner daiichi sankyo mdm inhibitor  phase  jak inhibitors atiindication dermatology partner aclaris jak inhibitors  preclinical tgfbeta inhibitorsindication cancerimmunotherapy partner bristolmyers squibb tgfb inhibitors  preclinical r azdindication asthma partner astrazeneca r azd  preclinical partnersponsored trials companysponsored trials pipeline overview fostamatinib – itp fostamatinib – aiha fostamatinib – igan partnered products aclaris therapeutics astrazeneca bergenbio bristolmyers squibb daiichi sankyo clinical trials publications rigel management team management team management team raul r rodriguez  president and chief executive officerraul r rodriguez is the president and chief executive officer of rigel and serves on our board of directors before being named ceo in november  mr rodriguez held management positions of increasing responsibility within the company most recently serving as president and chief operating officer since june  he joined rigel as vice president business development in april  prior to his employment at rigel mr rodriguez was senior vice president business development and operations for ontogeny inc now curis executive director business development and market planning for scios inc now jj and held various positions at gd searle  company now pfizer after earning his ab from harvard college mr rodriguez went on to earn his masters of public health at the university of illinois and his mba at the stanford graduate school of business annemarie duliege md  executive vice president and chief medical officer annemarie duliege md ms has served as our executive vice president and chief medical officer since march  prior to joining rigel dr duliege was chief of strategic development and head of immunooncology at chemocentryx inc from  to  dr duliege was at affymax inc initially as vice president clinical medical and regulatory affairs and then as chief medical officer at affymax she grew the clinical development organization and successfully managed the development of its first marketed product through international clinical studies resulting in nda approval by the fda in that role she was responsible for working closely with the fda on product label and postmarketing requirements as well as the strategy and implementation of significant postlaunch epidemiological studies she was also responsible for providing critical pipeline development results in support of the affymax initial public offering and followon public offerings led a major partnership with takeda inc and contributed to business development projects before affymax dr duliege worked at chiron and genentech dr duliege received her doctorate of medicine her certification in pediatrics and an ms in biostatistics from paris medical school and an ms in epidemiology from the harvard school of public health she is an adjunct clinical assistant professor at stanford’s school of medicine and the lucile packard children’s hospital she also serves on the board of the cirm the california institute for regenerative medicine eldon c mayer iii  executive vice president and chief commercial officer eldon c mayer iii was appointed as executive vice president and chief commercial officer in october  prior to joining rigel mr mayer successfully led the commercial strategy function at questcor pharmaceuticals a specialty biopharma company that focused on serious ultrarare diseases as head of commercial operations mr mayer launched a drug in many new indications building out a specialty commercial team from  to nearly  people and growing annual sales to over  billion prior to that he held positions of increasing responsibility at a number of biopharma companies including scheringplough alza chiron and connetics in functional areas including strategic planning marketing sales market researchanalytics operations and finance mr mayer serves as a member of the board of directors for promet therapeutics llc and the national community oncology dispensing association mr mayer holds a bs in finance from fairleigh dickinson university and an mba in marketing from syracuse university dolly vance  executive vice president corporate affairs and general counseldolly vance has been our executive vice president corporate affairs and general counsel since may  ms vance is also rigels corporate secretary a title she has held since  she was appointed senior vice president and general counsel in  and was appointed general counsel and vice president of intellectual property in january  she joined rigel in september  as rigels first inhouse counsel from  until september  she was at the law firm of flehr hohbach test albritton  herbert now dorsey  whitney where she was a partner prior to law school she worked in various research laboratories including the laboratory of norman davidson at california institute of technology she holds a bachelors degree from university of california san diego and a jd degree from boston university school of law ryan maynard  executive vice president and chief financial officerryan maynard was appointed executive vice president and chief financial officer in may  he had previously served as vice president and chief financial officer since january  after being named vice president of finance and acting chief financial officer in june  mr maynard joined rigel as corporate controller in september  and was appointed as an assistant secretary in october  he is also a member of the board of directors of lion biotechnologies inc prior to joining rigel mr maynard was corporate controller and director of finance  accounting for personify inc an ecommerce software company from november  to april  from july  to october  he served as controller of general magic inc and from july  to june  he held various positions at siliconix inc most recently as senior finance manager he previously worked at ernst  young llp where he became a certified public accountant mr maynard holds a bs degree in commerce  accounting from santa clara university esteban masuda phd  senior vice president researchesteban masuda phd was appointed senior vice president research in september  before being named to that position dr masuda held the title of senior vice president immunology since  he joined rigel as a scientist in  he has worked on and led numerous drug discovery projects in inflammatory and allergic diseases and served as the first project leader of the program that led to the discovery of fostamatinib his work has resulted in moving several product candidates into clinical development establishing various corporate partnerships producing  publications and issuing  us patents prior to joining rigel dr masuda spent seven years at dnax research institute of molecular and cellular biology in cytokine biology he received a bs in biochemistry from university of california riverside and a phd in molecular genetics from hiroshima university japan joseph lasaga  vice president business development and alliance managementjoseph lasaga was appointed vice president business development and alliance management in october  prior to rejoining rigel mr lasaga was vice president business development and alliance management at galena biopharma inc where he was responsible for managing corporate and business development strategy and activities from  until  mr lasaga was director and later named senior director business development at nektar therapeutics where he led licensing activities managed key alliances and structured research collaborations he began his career at rigel in  working in research before moving into business development most recently as associate director in that role he served as the alliance manager for all of rigel’s partners was an integral member of the negotiating team for rigel’s outlicensing of fostamatinib to astrazeneca in early  and managed all other aspects of business development mr lasaga graduated from san jose state university with a bs in molecular biology and earned his mba in marketing from san francisco state university about rigel management team board of directors partnering with rigel contact us contact us – rigel contact us contact rigel our address  veterans blvd south san francisco ca  call us tel  fax  have any questions pubrelrigelcom about rigel management team board of directors partnering with rigel contact us rigel fostamatinib itp fostamatinib – itp fostamatinib oral syk inhibitor for itp immune thrombocytopenic purpura itp is an autoimmune disease where the immune system attacks and destroys platelets in the blood the result  abnormally low platelet counts there are two forms of itp acute thrombocytopenic purpura which is most commonly seen in young children and chronic thrombocytopenic purpura which requires continual follow up care with a hematologist there are approximately  to  patients with itp in the us and it qualifies as an orphan disease rigel is focusing its fostamatinib itp program on the chronic form of this disorder targeting the underlying autoimmune cause of the disease rather than stimulating platelet production antibodies usually of the igg type mediate platelet destruction in itp fostamatinib has a novel mechanism of action blocking igg receptor signaling in both macrophages and b cells via syk kinase rigel completed and reported results from the fit phase  clinical program of fostamatinib in itp in  rigel submitted an nda to the fda for fostamatinib in patients with chronic or persistent itp in april  publication  of mice and men an openlabel pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of syk clinical trials phase   itp  phase   itp  pipeline overview fostamatinib – itp fostamatinib – aiha fostamatinib – igan partnered products aclaris therapeutics astrazeneca bergenbio bristolmyers squibb daiichi sankyo clinical trials publications rigel pharmaceuticals corporate overview about about rigel company overview rigel pharmaceuticals inc is a biotechnology company dedicated to discovering developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematological disorders cancer and rare diseases rigels pioneering research focuses on signaling pathways that are critical to disease mechanisms our business strategy is to transition to a commercialstage company with our phase  results from fostamatinib in immune thrombocytopenic purpura itp we continue to build an extensive portfolio of products monetizing select assets through attractive partnerships rigel’s current clinical programs include clinical trials of fostamatinib an oral spleen tyrosine kinase syk inhibitor in a number of indications the company has submitted an nda to the fda for fostamatinib in patients with chronic or persistent itp the investigation of fostamatinib also includes phase  clinical trials for autoimmune hemolytic anemia and iga nephropathy in addition rigel has product candidates in development with partners bergenbio as daiichi sankyo and aclaris therapeutics about rigel management team board of directors partnering with rigel contact us rigel fact sheet rigel pipeline pipeline pipeline product  indication pre clinical phase  phase  phase  nda review fostamatinib  itpindication immune thrombocytopeniatarget syk fostamatinib itp  phase  fostamatinib  iganindication iga nephropathy target syk fostamatinib igan  phase  fostamatinib  aihaindication autoimmune hemolytic anemiatarget syk fostamatinib aiha  phase  r bgbindication cancer partner bergenbio r bgb  phase b mdm inhibitor dsindication cancer partner daiichi sankyo mdm inhibitor  phase  jak inhibitors atiindication dermatology partner aclaris jak inhibitors  preclinical tgfbeta inhibitorsindication cancerimmunotherapy partner bristolmyers squibb tgfb inhibitors  preclinical r azdindication asthma partner astrazeneca r azd  preclinical partnersponsored trials companysponsored trials pipeline overview fostamatinib – itp fostamatinib – aiha fostamatinib – igan partnered products aclaris therapeutics astrazeneca bergenbio bristolmyers squibb daiichi sankyo clinical trials publications rigel pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports rigel pharmaceuticals inc  product pipeline review   rigel pharmaceuticals inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports rigel pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘rigel pharmaceuticals inc  product pipeline review  ’ provides an overview of the rigel pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of rigel pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of rigel pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of rigel pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the rigel pharmaceuticals inc’s pipeline productsreasons to buy evaluate rigel pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of rigel pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the rigel pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of rigel pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of rigel pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of rigel pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures rigel pharmaceuticals inc snapshot rigel pharmaceuticals inc overview key information key facts rigel pharmaceuticals inc  research and development overview key therapeutic areas rigel pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities rigel pharmaceuticals inc  pipeline products glance rigel pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities rigel pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities rigel pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities rigel pharmaceuticals inc  drug profiles fostamatinib disodium product description mechanism of action rd progress r product description mechanism of action rd progress small molecule to inhibit growth and differentiation factor  for ventilator atrophy product description mechanism of action rd progress small molecule to inhibit protein kinase c theta for autoimmune disorders product description mechanism of action rd progress small molecules to antagonize tgf beta receptor for cancer product description mechanism of action rd progress rigel pharmaceuticals inc  pipeline analysis rigel pharmaceuticals inc  pipeline products by target rigel pharmaceuticals inc  pipeline products by route of administration rigel pharmaceuticals inc  pipeline products by molecule type rigel pharmaceuticals inc  pipeline products by mechanism of action rigel pharmaceuticals inc  recent pipeline updates rigel pharmaceuticals inc  dormant projects rigel pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles fostamatinib disodium r r rigel pharmaceuticals inc  company statement rigel pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesrigel pharmaceuticals inc key information rigel pharmaceuticals inc key facts rigel pharmaceuticals inc  pipeline by indication  rigel pharmaceuticals inc  pipeline by stage of development  rigel pharmaceuticals inc  monotherapy products in pipeline  rigel pharmaceuticals inc  partnered products in pipeline  rigel pharmaceuticals inc  partnered products combination treatment modalities  rigel pharmaceuticals inc  outlicensed products in pipeline  rigel pharmaceuticals inc  outlicensed products combination treatment modalities  rigel pharmaceuticals inc  phase iii  rigel pharmaceuticals inc  phase ii  rigel pharmaceuticals inc  preclinical  rigel pharmaceuticals inc  pipeline by target  rigel pharmaceuticals inc  pipeline by route of administration  rigel pharmaceuticals inc  pipeline by molecule type  rigel pharmaceuticals inc  pipeline products by mechanism of action  rigel pharmaceuticals inc  recent pipeline updates  rigel pharmaceuticals inc  dormant developmental projects rigel pharmaceuticals inc  discontinued pipeline products  list of figuresrigel pharmaceuticals inc  pipeline by top  indication  rigel pharmaceuticals inc  pipeline by stage of development  rigel pharmaceuticals inc  monotherapy products in pipeline  rigel pharmaceuticals inc  outlicensed products in pipeline  rigel pharmaceuticals inc  pipeline by top  target  rigel pharmaceuticals inc  pipeline by top  route of administration  rigel pharmaceuticals inc  pipeline by top  molecule type  rigel pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send rigel pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report rigel pharmaceuticals inc  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license rigel pharmaceuticals inc  product pipeline review   published may   content info  pages description summary global markets directs rigel pharmaceuticals inc  product pipeline review   provides an overview of the rigel pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of rigel pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of rigel pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of rigel pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the rigel pharmaceuticals incs pipeline products reasons to buy evaluate rigel pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of rigel pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the rigel pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of rigel pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of rigel pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of rigel pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures rigel pharmaceuticals inc snapshot rigel pharmaceuticals inc overview key information key facts rigel pharmaceuticals inc  research and development overview key therapeutic areas rigel pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities rigel pharmaceuticals inc  pipeline products glance rigel pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities rigel pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities rigel pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities rigel pharmaceuticals inc  drug profiles fostamatinib disodium product description mechanism of action rd progress r product description mechanism of action rd progress small molecule to inhibit growth and differentiation factor  for ventilator atrophy product description mechanism of action rd progress small molecule to inhibit protein kinase c theta for autoimmune disorders product description mechanism of action rd progress small molecules to antagonize tgf beta receptor for cancer product description mechanism of action rd progress rigel pharmaceuticals inc  pipeline analysis rigel pharmaceuticals inc  pipeline products by target rigel pharmaceuticals inc  pipeline products by route of administration rigel pharmaceuticals inc  pipeline products by molecule type rigel pharmaceuticals inc  pipeline products by mechanism of action rigel pharmaceuticals inc  recent pipeline updates rigel pharmaceuticals inc  dormant projects rigel pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles fostamatinib disodium r r rigel pharmaceuticals inc  company statement rigel pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables rigel pharmaceuticals inc key information rigel pharmaceuticals inc key facts rigel pharmaceuticals inc  pipeline by indication  rigel pharmaceuticals inc  pipeline by stage of development  rigel pharmaceuticals inc  monotherapy products in pipeline  rigel pharmaceuticals inc  partnered products in pipeline  rigel pharmaceuticals inc  partnered products combination treatment modalities  rigel pharmaceuticals inc  outlicensed products in pipeline  rigel pharmaceuticals inc  outlicensed products combination treatment modalities  rigel pharmaceuticals inc  phase iii  rigel pharmaceuticals inc  phase ii  rigel pharmaceuticals inc  preclinical  rigel pharmaceuticals inc  pipeline by target  rigel pharmaceuticals inc  pipeline by route of administration  rigel pharmaceuticals inc  pipeline by molecule type  rigel pharmaceuticals inc  pipeline products by mechanism of action  rigel pharmaceuticals inc  recent pipeline updates  rigel pharmaceuticals inc  dormant developmental projects rigel pharmaceuticals inc  discontinued pipeline products  list of figures rigel pharmaceuticals inc  pipeline by top  indication  rigel pharmaceuticals inc  pipeline by stage of development  rigel pharmaceuticals inc  monotherapy products in pipeline  rigel pharmaceuticals inc  outlicensed products in pipeline  rigel pharmaceuticals inc  pipeline by top  target  rigel pharmaceuticals inc  pipeline by top  route of administration  rigel pharmaceuticals inc  pipeline by top  molecule type  rigel pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved rigel pharmaceuticals inc nasdaqrigl rigel pharmaceuticals inc rigl product news news  stocknewscom     follow us stocktwits twitter rigel pharmaceuticals inc rigl product news news rigl – announces that the fda has accepted the new drug application for tavalisse fostamatinib disodium in patients with chronic or persistent immune thrombocytopenia jun    am  by stocknewscom staff product news key facts surrounding this news item rigl had a powr rating of d sell coming into today rigl was  above its day moving average coming into today rigl was  above its day moving average coming into today rigl was  below its day moving average coming into today rigl was  below its day moving average coming into today rigl was  below its day moving average coming into today rigl had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about rigel pharmaceuticals inc rigl rigel pharmaceuticals inc engages in the discovery and development of smallmolecule drugs for the treatment of inflammatory and autoimmune diseases immunooncology related diseases and muscle disorders the company was founded in  and is based in south san francisco california view our full rigl ticker page with ratings news and more rigl at a glance rigl current powr rating™ overall powr rating™ rigl current price   more rigl ratings data and news rigl price reaction the day of this event jun  rigl closing price rigl volume from avgleading up to this eventrigl mo returnafter this eventrigl day returnrigl day returnrigl day return rigl price chart more rigel pharmaceuticals inc rigl news view all eventdate symbol news detail start price end price change powr rating loading please wait view all rigl news page generated in  seconds rigl key statistics  rigel pharmaceuticals inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close rigel pharmaceuticals inc nasdaq rigl go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus rigel pharmaceuticals inc after hours  quotes are delayed by  min jul    pm rigl quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description rigel pharmaceuticals inc is a clinical stage biotechnology company it discovers and develops novel targeted drugs in the therapeutic areas of immunology oncology and immune oncology the company focuses on intracellular signaling pathways and related targets that are critical to disease mechan rigel pharmaceuticals inc is a clinical stage biotechnology company it discovers and develops novel targeted drugs in the therapeutic areas of immunology oncology and immune oncology the company focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms its current product development programs include fostamatinib oral syk inhibitor and r topical ophthalmic jaksyk inhibitor rigel pharmaceuticals was founded by donald g payan garry p nolan and ronald b garren on june   and is headquartered in south san francisco ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr gary a lyons   chairman mr raul r rodriguez   president  chief executive officer mr ryan d maynard   cfo executive vp  headinvestor relations dr esteban s masuda   senior vice presidentresearch dr annemarie s duliege   chief medical officer  executive vice president insider actions – purchase – sale  – number of transactions  date name shares transaction value  annemarie s duliege chief medical officer    disposition at  per share   annemarie s duliege chief medical officer    disposition at  per share   donald g payan evp pres discoveryresearch director    disposition at  per share   donald g payan evp pres discoveryresearch director    disposition at  per share   donald g payan evp pres discoveryresearch director    derivativenonderivative trans at  per share   donald g payan evp pres discoveryresearch director    disposition at  per share   dolly a vance evp corp affairs gc sect    disposition at  per share   donald g payan evp pres discoveryresearch director    disposition at  per share   donald g payan evp pres discoveryresearch director    disposition at  per share   bvf partners lp    disposition at  per share   bvf partners lp    disposition at  per share   bvf partners lp    acquisition at  per share   bvf partners lp    acquisition at  per share  newslatestcompanyusrigl marketwatch news on rigl rigel’s stock rocked as allin drug disappoints in latestage trial  pm oct    tomi kilgore rigel pharmaceuticals stock on track to open at mo low  am oct    tomi kilgore rigel pharmaceuticals stock plunges  premarket after drug trial disappoints  am oct    tomi kilgore rigel pharmaceuticals cuts  of workforce to refocus on fostamatinib  am sept    ciara linnane rigel cofounder donald payan retires  am sept    ciara linnane rigel expects to save  to  mln annually  am sept    ciara linnane rigel expects to book  mln in restructuring charges mostly in q  am sept    ciara linnane rigel pharmaceuticals cuts  jobs or  of workforce  am sept    ciara linnane rigel says it will focus on commercializing fostamatinib  am sept    ciara linnane rigel pharmaceuticals started at outperform with  stock price target at bmo capital  am aug    tomi kilgore  stocks to watch  pm april    the trading deck astrazeneca m charge related to fostamatinib  am june    marketwatchcom rigel pharma down  in premarket trades  am dec    steve gelsi wednesday’s biggest gaining and declining stocks  pm oct    marketwatch rigel prices offering at  discount  am oct    marketwatchcom four companies unveil stock offerings  am oct    marketwatchcom  biotech stocks hit week highs  pm july    val brickates kennedy tuesdays biggest gaining and declining stocks  pm feb    marketwatch barclays rise fuels london gains  pm feb    sarah turner rigel pharmaceuticals shares down   am feb    nick godt loading more headlines newsnonmarketwatchcompanyusrigl other news on rigl omeros pipeline starting to get the recognition it deserves  am july    seeking alpha dova pharmaceuticals a different business model could lead to success  pm june    seeking alpha great point partners llc buys concert pharmaceuticals inc rigel pharmaceuticals inc ptc   pm june    gurufocuscom  things in biotech you should learn today june    pm june    seeking alpha rigel pharmaceuticals nda for tavalisse accepted by fda  am june    zackscom company news for june    am june    zackscom heres why rigel pharmaceuticals inc is shining extra bright today  pm june    motley fool fda accepts rigels marketing application for tavalisse for immune thrombocytopenia action date april   shares ahead  premarket  am june    seeking alpha implied volatility surging for rigel pharmaceuticals rigl stock options  am june    zackscom rigel pharma tavalisse nda will be a gamechanger  pm may    seeking alpha  biotech stocks id buy right now  pm may    motley fool rigel pharmaceuticals rigl ceo raul rodriguez on q  results  earnings call transcript  pm may    seeking alpha rigel pharmaceuticals inc  q  results  earnings call slides  pm may    seeking alpha q rigel pharmaceuticals inc  pm may    edgar online  edg  q k notable earnings after tuesday’s close  pm may    seeking alpha why rigel pharmaceuticals investors should come back later  pm april    seeking alpha rigel pharmaceuticals files nda for thrombocytopenia drug  am april    zackscom premarket gainers as of  am  am april    seeking alpha rigel submits us marketing application for fostamatinib for treatmentresistant itp  pm april    seeking alpha  top breakout stocks to boost your portfolio  am march    zackscom loading more headlines at a glance rigel pharmaceuticals inc  veterans boulevard south san francisco california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m employees  annual report for rigl newspressreleasecompanyusrigl press releases on rigl technical snapshots for these generic drugs stocks  horizon pharma mylan neurocrine biosciences and rigel pharma  am july    pr newswire  prf rigel announces oral presentation of tavalisse™ fostamatinib disodium phase  clinical data at the european hematology association nd annual congress  pm june    pr newswire  prf todays research reports on stocks to watch rigel pharmaceuticals and bellicum pharmaceuticals  am june    accesswire fda accepts rigels new drug application for tavalisse™ fostamatinib disodium for the treatment of chronic itp  am june    pr newswire  prf breakfast technical briefing on generic drugs stocks  innocoll rigel pharma tetraphase pharma and catalent  am june    pr newswire  prf rigel to present at jefferies  global healthcare conference  am june    pr newswire  prf rigel announces first quarter  financial results and provides company update  pm may    pr newswire  prf investor network rigel pharmaceuticals inc to host earnings call  am may    accesswire rigel announces tavalisse™ as proprietary name for fostamatinib in the united states  am april    pr newswire  prf technical reports on generic drugs stocks  mylan allergan horizon pharma and rigel pharma  am april    pr newswire  prf rigel announces conference call and webcast to report first quarter  financial results  am april    pr newswire  prf rigel submits new drug application to fda for fostamatinib in chronic itp  pm april    pr newswire  prf how these generic drugs stocks are faring  neurocrine biosciences lannett rigel pharma and catalent  am march    pr newswire  prf rigel announces fourth quarter  and year end  financial results and provides company update  pm march    pr newswire  prf rigel announces conference call and webcast to report fourth quarter and year end  financial results  am feb    pr newswire  prf rigel announces closing of public offering of common stock and full exercise of option to purchase additional shares  pm feb    pr newswire  prf rigel announces pricing of public offering of common stock  am jan    pr newswire  prf rigel announces proposed public offering of common stock  pm jan    pr newswire  prf fostamatinib study results continue to trend positive  am jan    pr newswire  prf generic drugs stocks on investors radar  ironwood pharma medicines rigel pharma and lannett  am jan    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeurozone composite pmi at  vs  factset estimate aeurozone services pmi  in july vs  factset estimate aeurozone manufacturing pmi at  in july vs  factset estimate ashares of european automakers fall after cartelclaims report aanglo american platinum swings to loss aanglo american platinum swings to loss afrances cac  opens  higher at  agermanys dax opens  lower at  afrances cac  opens  higher at  auks ftse  opens  lower at  astoxx europe  opens  higher at  atrump to make statement on healthcare monday reports areckitt benckiser profit rises on reduced costs achinese regulator tells insurers to shape up arandgold looks to get more out of tongon mine aryanair profit soars  warns on overcapacity asiemens and bombardier in talks to form train jvs avw asks eu to scrutinize german car makers akkr close to announcing deal for webmd ajulius baer assets under management jump loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  rigel pharmaceuticals inc private company information  bloomberg july    am et biotechnology company overview of rigel pharmaceuticals inc snapshot people company overview rigel pharmaceuticals inc a clinicalstage biotechnology company engages in the discovery and development of drugs in the therapeutic areas of immunology oncology and immunooncology the company’s clinical programs include fostamatinib an oral spleen tyrosine kinase syk inhibitor which has completed phase iii clinical program for immune thrombocytopenia purpura and phase ii clinical study for autoimmune hemolytic anemia and iga nephropathy it is also developing two oncology product candidates which are in phase i and phase ii rigel pharmaceuticals inc has license agreements with aclaris therapeutics international limited for the development and commercialization of janus kin rigel pharmaceuticals inc a clinicalstage biotechnology company engages in the discovery and development of drugs in the therapeutic areas of immunology oncology and immunooncology the company’s clinical programs include fostamatinib an oral spleen tyrosine kinase syk inhibitor which has completed phase iii clinical program for immune thrombocytopenia purpura and phase ii clinical study for autoimmune hemolytic anemia and iga nephropathy it is also developing two oncology product candidates which are in phase i and phase ii rigel pharmaceuticals inc has license agreements with aclaris therapeutics international limited for the development and commercialization of janus kinase jak inhibitors for the treatment of alopecia areata and other dermatological conditions bristolmyers squibb company for the discovery development and commercialization of cancer immunotherapies astrazeneca ab for the development and commercialization of r an inhaled jak inhibitor bergenbio as for the development and commercialization of an oncology program and daiichi sankyo to pursue research related to ligases the company was founded in  and is based in south san francisco california detailed description  veterans boulevardsouth san francisco ca united statesfounded in  employees phone  fax  wwwrigelcom key executives for rigel pharmaceuticals inc mr raul r rodriguez chief executive officer president and director age  total annual compensation k mr ryan d maynard chief financial officer and executive vice president age  total annual compensation k ms dolly a vance executive vice president of corporate affairs general counsel and corporate secretary age  total annual compensation k dr annemarie s duliege md ms chief medical officer and executive vice president age  total annual compensation k mr eldon c mayer iii chief commercial officer and executive vice president age  total annual compensation k compensation as of fiscal year  rigel pharmaceuticals inc key developments rigel pharmaceuticals inc presents at jefferies  global healthcare conference jun  am jun   rigel pharmaceuticals inc presents at jefferies  global healthcare conference jun  am venue grand hyatt  e nd st new york new york united states speakers ryan d maynard chief financial officer and executive vice president rigel pharmaceuticals inc reports unaudited earnings results for the first quarter ended march   may   rigel pharmaceuticals inc reported unaudited earnings results for the first quarter ended march   for the quarter the company reported contract revenues from collaborations of  compared to  a year ago loss from operations was  compared to  a year ago net loss was  or  per basic and diluted share compared to  or  per basic and diluted share a year ago rigel pharmaceuticals receives approval from food and drug administration for tavalisse as proprietary name for fostamatinib in the united states apr   rigel pharmaceuticals inc announced that the us food and drug administration fda has conditionally accepted the proprietary name tavalisse™ for the companys investigational product candidate fostamatinib disodium an oral spleen tyrosine kinase syk inhibitor in addition rigel has applied to the us patent and trademark office to obtain federal registration of the tavalisse mark the name tavalisse pronounced  ta vah lees was developed based on the fdas guidance for industry contents of a complete submission for the evaluation of proprietary names created with the help of experts in this field the proprietary name development included input from prescribers pharmacists linguists and employees to create a unique and approachable name earlier this month the company announced that it submitted a new drug application nda to the fda for tavalisse in patients with chronic and persistent immune thrombocytopenia itp the fda previously granted orphan drug designation to tavalisse for the treatment of patients with itp the nda is supported by data from the phase  clinical program for tavalisse in itp which was comprised of three studies two randomized placebocontrolled studies studies  and  and an openlabel extension study study  in total  itp patients have been treated with tavalisse and included in the nda submission across all indications tavalisse has been evaluated in over  subjects similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact rigel pharmaceuticals inc please visit wwwrigelcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close rigl stock price  rigel pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern a eurozone composite pmi at  vs  factset estimate a eurozone services pmi  in july vs  factset estimate a eurozone manufacturing pmi at  in july vs  factset estimate a shares of european automakers fall after cartelclaims report a anglo american platinum swings to loss a updated anglo american platinum swings to loss a frances cac  opens  higher at  a germanys dax opens  lower at  a frances cac  opens  higher at  a uks ftse  opens  lower at  to be replaced home investing quotes stocks united states rigl overview compare quotes stock screener earnings calendar sectors nasdaq rigl us nasdaq join td ameritrade find a broker rigel pharmaceuticals inc watchlist createriglalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones rigel’s stock rocked as allin drug disappoints in latestage trial oct   at  pm et by tomi kilgore rigel pharmaceuticals stock on track to open at mo low oct   at  am et by tomi kilgore rigel pharmaceuticals stock plunges  premarket after drug trial disappoints oct   at  am et by tomi kilgore rigel pharmaceuticals cuts  of workforce to refocus on fostamatinib sep   at  am et by ciara linnane rigel cofounder donald payan retires sep   at  am et by ciara linnane rigel expects to save  to  mln annually sep   at  am et by ciara linnane rigel expects to book  mln in restructuring charges mostly in q sep   at  am et by ciara linnane rigel pharmaceuticals cuts  jobs or  of workforce sep   at  am et by ciara linnane rigel says it will focus on commercializing fostamatinib sep   at  am et by ciara linnane rigel pharmaceuticals started at outperform with  stock price target at bmo capital aug   at  am et by tomi kilgore  stocks to watch apr   at  pm et by harry boxer astrazeneca m charge related to fostamatinib jun   at  am et rigel pharma down  in premarket trades dec   at  am et by steve gelsi wednesday’s biggest gaining and declining stocks oct   at  pm et by marketwatch rigel prices offering at  discount oct   at  am et four companies unveil stock offerings oct   at  am et  biotech stocks hit week highs jul   at  pm et by val brickates kennedy tuesdays biggest gaining and declining stocks feb   at  pm et by marketwatch barclays rise fuels london gains feb   at  pm et by sarah turner rigel pharmaceuticals shares down  feb   at  am et by nick godt stocks to watch dish armstrong world industries darden restaurants feb   at  am et on the wall street journal stocks to watch macys deere seaworld aug   at  am et on the wall street journal stocks to watch mckesson generac arctic cat oct   at  am et on the wall street journal stocks to watch amgen rigel pharma merge healthcare aug   at  am et on the wall street journal stocks to watch exacttarget dollar general giii apparel jun   at  am et on the wall street journal stocks to watch best buy clearwire cvs caremark dec   at  am et on the wall street journal stocks to watch metropcs best buy xyratex oct   at  am et on the wall street journal stocks to watch netapp tiffany computer sciences radioshack and more may   at  am et on the wall street journal curing the headache at fosters feb   at  pm et on the wall street journal adverse reaction to astrazenecas rigel deal is justified feb   at  pm et on the wall street journal neutral tandem climbs rigel sinks feb   at  pm et on the wall street journal astrazeneca rigel to collaborate on arthritis drug feb   at  am et on the wall street journal rigel pharma gives up gains dec   at  pm et on barrons online rigel activity may point to further gains dec   at  pm et on the wall street journal scottish re group pf b rigel pharmaceuticals biggest price gainers sctb rigl dec   at  pm et on the wall street journal moneygram intl rigel pharmaceuticals biggest price gainers mgi rigl dec   at  pm et on the wall street journal premarket dows chemical venture dec   at  am et on the wall street journal noted    jun   at  am et on the wall street journal small caps close slightly higher aug   at  am et on the wall street journal rigel drugs to be tested on humans may   at  pm et on the wall street journal recent news other news press releases omeros pipeline starting to get the recognition it deserves omeros pipeline starting to get the recognition it deserves jul   at  am et on seeking alpha dova pharmaceuticals a different business model could lead to success dova pharmaceuticals a different business model could lead to success jun   at  pm et on seeking alpha great point partners llc buys concert pharmaceuticals inc rigel pharmaceuticals inc ptc  great point partners llc buys concert pharmaceuticals inc rigel pharmaceuticals inc ptc therapeutics inc sells enanta pharmaceuticals inc merrimack pharmaceuticals inc colucid pharmaceuticals inc jun   at  pm et on gurufocuscom rigel pharmaceuticals nda for tavalisse accepted by fda rigel pharmaceuticals inc rigl announced that the fda has accepted its new drug application nda seeking approval for its oral spleen tyrosine kinase inhibitor fostamatinib for the treatment of patients with chronic and persistent immune thrombocytopenia jun   at  am et on zackscom company news for june   companies in the news are riceeqtriglnvdqsykvrx jun   at  am et on zackscom  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  pm et on seeking alpha heres why rigel pharmaceuticals inc is shining extra bright today jun   at  pm et on motley fool fda accepts rigels marketing application for tavalisse for immune thrombocytopenia action date april   shares ahead  premarket fda accepts rigels marketing application for tavalisse for immune thrombocytopenia action date april   shares ahead  premarket jun   at  am et on seeking alpha implied volatility surging for rigel pharmaceuticals rigl stock options investors in rigel pharmaceuticals inc rigl need to pay close attention to the stock based on moves in the options market lately jun   at  am et on zackscom rigel pharma tavalisse nda will be a gamechanger rigel pharma tavalisse nda will be a gamechanger may   at  pm et on seeking alpha  biotech stocks id buy right now may   at  pm et on motley fool rigel pharmaceuticals rigl ceo raul rodriguez on q  results  earnings call transcript rigel pharmaceuticals rigl ceo raul rodriguez on q  results  earnings call transcript may   at  pm et on seeking alpha rigel pharmaceuticals inc  q  results  earnings call slides rigel pharmaceuticals inc  q  results  earnings call slides may   at  pm et on seeking alpha q rigel pharmaceuticals inc q rigel pharmaceuticals inc may   at  pm et on edgar online  edg  q k notable earnings after tuesday’s close notable earnings after tuesday’s close may   at  pm et on seeking alpha why rigel pharmaceuticals investors should come back later apr   at  pm et on seeking alpha rigel pharmaceuticals files nda for thrombocytopenia drug apr   at  am et on zackscom premarket gainers as of  am apr   at  am et on seeking alpha rigel submits us marketing application for fostamatinib for treatmentresistant itp apr   at  pm et on seeking alpha  top breakout stocks to boost your portfolio mar   at  am et on zackscom technical snapshots for these generic drugs stocks  horizon pharma mylan neurocrine biosciences and rigel pharma technical snapshots for these generic drugs stocks  horizon pharma mylan neurocrine biosciences and rigel pharma jul   at  am et on pr newswire  prf rigel announces oral presentation of tavalisse™ fostamatinib disodium phase  clinical data at the european hematology association nd annual congress rigel announces oral presentation of tavalisse™ fostamatinib disodium phase  clinical data at the european hematology association nd annual congress jun   at  pm et on pr newswire  prf todays research reports on stocks to watch rigel pharmaceuticals and bellicum pharmaceuticals todays research reports on stocks to watch rigel pharmaceuticals and bellicum pharmaceuticals jun   at  am et on accesswire fda accepts rigels new drug application for tavalisse™ fostamatinib disodium for the treatment of chronic itp fda accepts rigels new drug application for tavalisse™ fostamatinib disodium for the treatment of chronic itp jun   at  am et on pr newswire  prf breakfast technical briefing on generic drugs stocks  innocoll rigel pharma tetraphase pharma and catalent breakfast technical briefing on generic drugs stocks  innocoll rigel pharma tetraphase pharma and catalent jun   at  am et on pr newswire  prf rigel to present at jefferies  global healthcare conference rigel to present at jefferies  global healthcare conference jun   at  am et on pr newswire  prf rigel announces first quarter  financial results and provides company update rigel announces first quarter  financial results and provides company update may   at  pm et on pr newswire  prf investor network rigel pharmaceuticals inc to host earnings call investor network rigel pharmaceuticals inc to host earnings call may   at  am et on accesswire rigel announces tavalisse™ as proprietary name for fostamatinib in the united states rigel announces tavalisse™ as proprietary name for fostamatinib in the united states apr   at  am et on pr newswire  prf technical reports on generic drugs stocks  mylan allergan horizon pharma and rigel pharma technical reports on generic drugs stocks  mylan allergan horizon pharma and rigel pharma apr   at  am et on pr newswire  prf rigel announces conference call and webcast to report first quarter  financial results rigel announces conference call and webcast to report first quarter  financial results apr   at  am et on pr newswire  prf rigel submits new drug application to fda for fostamatinib in chronic itp apr   at  pm et on pr newswire  prf how these generic drugs stocks are faring  neurocrine biosciences lannett rigel pharma and catalent mar   at  am et on pr newswire  prf rigel announces fourth quarter  and year end  financial results and provides company update mar   at  pm et on pr newswire  prf rigel announces conference call and webcast to report fourth quarter and year end  financial results feb   at  am et on pr newswire  prf rigel announces closing of public offering of common stock and full exercise of option to purchase additional shares feb   at  pm et on pr newswire  prf rigel announces pricing of public offering of common stock jan   at  am et on pr newswire  prf rigel announces proposed public offering of common stock jan   at  pm et on pr newswire  prf fostamatinib study results continue to trend positive jan   at  am et on pr newswire  prf generic drugs stocks on investors radar  ironwood pharma medicines rigel pharma and lannett jan   at  am et on pr newswire  prf rigel pharmaceuticals inc rigel pharmaceuticals inc is a clinical stage biotechnology company it discovers and develops novel targeted drugs in the therapeutic areas of immunology oncology and immune oncology the company focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms its current product development programs include fostamatinib oral syk inhibitor and r topical ophthalmic jaksyk inhibitor rigel pharmaceuticals was founded by donald g payan garry p nolan and ronald b garren on june   and is headquartered in south san francisco ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings  biggest price target changes for thursday sep   at  am et on benzingacom bmo thinks rigels fostamatinib market opportunity will be further validated sep   at  am et on benzingacom bmo analysts initiate coverage on rigel pharma seeing  upside aug   at  pm et on benzingacom competitors name chg  market cap amgen inc  b sangamo therapeutics inc  m infinity pharmaceuticals inc  m astrazeneca plc adr  b chemocentryx inc  m competitor data provided by partner content trending tickers powered by srpt  bzun  crbp  dgaz  nyt  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeurozone composite pmi at  vs  factset estimate aeurozone services pmi  in july vs  factset estimate aeurozone manufacturing pmi at  in july vs  factset estimate ashares of european automakers fall after cartelclaims report aanglo american platinum swings to loss aanglo american platinum swings to loss afrances cac  opens  higher at  agermanys dax opens  lower at  afrances cac  opens  higher at  auks ftse  opens  lower at  astoxx europe  opens  higher at  atrump to make statement on healthcare monday reports areckitt benckiser profit rises on reduced costs achinese regulator tells insurers to shape up arandgold looks to get more out of tongon mine aryanair profit soars  warns on overcapacity asiemens and bombardier in talks to form train jvs avw asks eu to scrutinize german car makers akkr close to announcing deal for webmd ajulius baer assets under management jump loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeurozone composite pmi at  vs  factset estimate aeurozone services pmi  in july vs  factset estimate aeurozone manufacturing pmi at  in july vs  factset estimate ashares of european automakers fall after cartelclaims report aanglo american platinum swings to loss aanglo american platinum swings to loss afrances cac  opens  higher at  agermanys dax opens  lower at  afrances cac  opens  higher at  auks ftse  opens  lower at  astoxx europe  opens  higher at  atrump to make statement on healthcare monday reports areckitt benckiser profit rises on reduced costs achinese regulator tells insurers to shape up arandgold looks to get more out of tongon mine aryanair profit soars  warns on overcapacity asiemens and bombardier in talks to form train jvs avw asks eu to scrutinize german car makers akkr close to announcing deal for webmd ajulius baer assets under management jump loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert new york markets open in market snapshot analyst ratings stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest aeurozone composite pmi at  vs  factset estimate aeurozone services pmi  in july vs  factset estimate aeurozone manufacturing pmi at  in july vs  factset estimate ashares of european automakers fall after cartelclaims report aanglo american platinum swings to loss aanglo american platinum swings to loss afrances cac  opens  higher at  agermanys dax opens  lower at  afrances cac  opens  higher at  auks ftse  opens  lower at  astoxx europe  opens  higher at  atrump to make statement on healthcare monday reports areckitt benckiser profit rises on reduced costs achinese regulator tells insurers to shape up arandgold looks to get more out of tongon mine aryanair profit soars  warns on overcapacity asiemens and bombardier in talks to form train jvs avw asks eu to scrutinize german car makers akkr close to announcing deal for webmd ajulius baer assets under management jump loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  market report rigel pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing rigel pharmaceuticals inc  product pipeline review   may    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs rigel pharmaceuticals inc  product pipeline review   provides an overview of the rigel pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of rigel pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of rigel pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of rigel pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the rigel pharmaceuticals incs pipeline productsreasons to buyevaluate rigel pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of rigel pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the rigel pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of rigel pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of rigel pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of rigel pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentslist of tableslist of figuresrigel pharmaceuticals inc snapshotrigel pharmaceuticals inc overviewkey informationkey factsrigel pharmaceuticals inc  research and development overviewkey therapeutic areasrigel pharmaceuticals inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  partnered productspartnered productscombination treatment modalitiespipeline products  outlicensed productsoutlicensed productscombination treatment modalitiesrigel pharmaceuticals inc  pipeline products glancerigel pharmaceuticals inc  late stage pipeline productsphase iii productscombination treatment modalitiesrigel pharmaceuticals inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesrigel pharmaceuticals inc  early stage pipeline productspreclinical productscombination treatment modalitiesrigel pharmaceuticals inc  drug profilesfostamatinib disodiumproduct descriptionmechanism of actionrd progressrproduct descriptionmechanism of actionrd progresssmall molecule to inhibit growth and differentiation factor  for ventilator atrophyproduct descriptionmechanism of actionrd progresssmall molecule to inhibit protein kinase c theta for autoimmune disordersproduct descriptionmechanism of actionrd progresssmall molecules to antagonize tgf beta receptor for cancerproduct descriptionmechanism of actionrd progressrigel pharmaceuticals inc  pipeline analysisrigel pharmaceuticals inc  pipeline products by targetrigel pharmaceuticals inc  pipeline products by route of administrationrigel pharmaceuticals inc  pipeline products by molecule typerigel pharmaceuticals inc  pipeline products by mechanism of actionrigel pharmaceuticals inc  recent pipeline updatesrigel pharmaceuticals inc  dormant projectsrigel pharmaceuticals inc  discontinued pipeline productsdiscontinued pipeline product profilesfostamatinib disodiumrrrigel pharmaceuticals inc  company statementrigel pharmaceuticals inc  locations and subsidiarieshead officeappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesrigel pharmaceuticals inc key informationrigel pharmaceuticals inc key factsrigel pharmaceuticals inc  pipeline by indication rigel pharmaceuticals inc  pipeline by stage of development rigel pharmaceuticals inc  monotherapy products in pipeline rigel pharmaceuticals inc  partnered products in pipeline rigel pharmaceuticals inc  partnered products combination treatment modalities rigel pharmaceuticals inc  outlicensed products in pipeline rigel pharmaceuticals inc  outlicensed products combination treatment modalities rigel pharmaceuticals inc  phase iii rigel pharmaceuticals inc  phase ii rigel pharmaceuticals inc  preclinical rigel pharmaceuticals inc  pipeline by target rigel pharmaceuticals inc  pipeline by route of administration rigel pharmaceuticals inc  pipeline by molecule type rigel pharmaceuticals inc  pipeline products by mechanism of action rigel pharmaceuticals inc  recent pipeline updates rigel pharmaceuticals inc  dormant developmental projectsrigel pharmaceuticals inc  discontinued pipeline products list of figuresrigel pharmaceuticals inc  pipeline by top  indication rigel pharmaceuticals inc  pipeline by stage of development rigel pharmaceuticals inc  monotherapy products in pipeline rigel pharmaceuticals inc  outlicensed products in pipeline rigel pharmaceuticals inc  pipeline by top  target rigel pharmaceuticals inc  pipeline by top  route of administration rigel pharmaceuticals inc  pipeline by top  molecule type rigel pharmaceuticals inc  pipeline products by top  mechanism of action  companies mentioned in this reportrigel pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc rigel pharmaceuticals new phase  study aiha research study now recruiting in the us learn more rigel submits nda for fostamatinib in chronic immune thrombocytopenia itp view press release pipeline news  events clinical trials investors rigel pharmaceuticals  office foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingrigel pharmaceuticalsofficesouth san franciscosavesharetips photos rigel pharmaceuticals tip and reviewlog in to leave a tip herepostchon qmarch  been here  timesscience photosrelated searchesrigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco photos  rigel pharmaceuticals south san francisco location  rigel pharmaceuticals south san francisco address  rigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfrigel pharmaceuticals veterans blvdsouth san francisco ca united statesget directions none listed see when people check inpeople tend to check in during these timestoday am–noon pm– pm pm– pmtue am– pmwed am–noon pm– pmthu am–noon pm– pmfrinoon– pm pm– pm pm– pmsat am– pmsun am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around yourigel pharmaceuticals  office foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingrigel pharmaceuticalsofficesouth san franciscosavesharetips photos rigel pharmaceuticals tip and reviewlog in to leave a tip herepostchon qmarch  been here  timesscience photosrelated searchesrigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco photos  rigel pharmaceuticals south san francisco location  rigel pharmaceuticals south san francisco address  rigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfrigel pharmaceuticals veterans blvdsouth san francisco ca united statesget directions none listed see when people check inpeople tend to check in during these timestoday am–noon pm– pm pm– pmtue am– pmwed am–noon pm– pmthu am–noon pm– pmfrinoon– pm pm– pm pm– pmsat am– pmsun am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around youa tip at rigel pharmaceuticals foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingrigel pharmaceuticalsofficesouth san franciscosavesharetips photos rigel pharmaceuticals tip and reviewlog in to leave a tip herepostchon qmarch  been here  timesscience photosrelated searchesrigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco photos  rigel pharmaceuticals south san francisco location  rigel pharmaceuticals south san francisco address  rigel pharmaceuticals south san francisco  rigel pharmaceuticals south san francisco  aboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeyfoursquare    lovingly made in nyc  sfrigel pharmaceuticals veterans blvdsouth san francisco ca united statesget directions none listed see when people check inpeople tend to check in during these timestoday am–noon pm– pm pm– pmtue am– pmwed am–noon pm– pmthu am–noon pm– pmfrinoon– pm pm– pm pm– pmsat am– pmsun am– pmsee moreis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one